Electrome Corp Information

Electrome is pioneering a new class of precision bioelectric therapeutics for pain, infection, and cancer. By leveraging decades of peer-reviewed science and AI, we are decoding the electrical operating system that regulates biology to develop first-in-class therapies and novel combination approaches across high-burden disease areas. Our integrated signal-based therapeutics platform enables rapid discovery, manufacturing, and deployment of bioelectric medicines into real-world clinical workflows at scale. The Electrome platform combines programmable pulsed electromagnetic field (PEMF) technologies with an AI-driven discovery engine to identify, validate, and optimize therapeutic electromagnetic signals to influence cellular function. This approach allows Electrome to move beyond traditional chemistry-based drug development, targeting bioelectric pathways that regulate inflammation, ion channel activity, gene expression, and cellular repair. The result is a scalable, non-pharmacologic modality with the potential to address conditions where existing treatments are limited, costly, or associated with significant side effects. Electrome’s commercialization strategy integrates FDA-cleared devices, digital care delivery, and enterprise healthcare infrastructure to accelerate adoption across direct-to-consumer, pharmacy, provider, and payer channels. With initial focus areas in chronic pain, recovery, and inflammation—and a pipeline extending into infectious disease and oncology—the company is positioned to deliver clinically validated, accessible therapies while building the foundational platform for the next generation of bioelectric medicine.